Adlai Nortye Group Ltd. (ANL)
ANL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$11.76
-17.34% on the day
Market cap
$757.0M
Small cap
Revenue
No annual revenue filed since the period ending 2023-12-31
Net income
No annual revenue filed since the period ending 2023-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ANL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Cayman Islands |
| IPO year | 2023 |
| SEC CIK | 0001944552 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2023-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 | POS AM | 2026-09-11 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-10 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-09-30 |
Source: SEC EDGAR submissions feed, 112 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -19.9% |
| 1 month | -25.0% |
| 3 months | -0.9% |
| Year to date | +692.3% |
| 1 year | +604.0% |
| From 52-week high | -32.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GYRE | Gyre Therapeutics Inc. | $6.71 | -2.26% | $748.2M |
| HELP | Helus Pharma Inc. | $10.50 | -4.80% | $767.1M |
| GERN | Geron Corporation | $1.20 | -1.64% | $771.0M |
| APMD | Apnimed Inc. | $17.83 | -4.29% | $742.3M |
| OBX | Obsidian Therapeutics Inc. | $11.99 | -6.25% | $740.7M |
| ARDX | Ardelyx Inc. | $3.12 | -3.41% | $777.5M |
| ANNX | Annexon Inc. | $3.83 | -3.28% | $726.1M |
| CRVS | Corvus Pharmaceuticals Inc. | $9.41 | -6.37% | $791.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier